| Followers | 238 |
| Posts | 15504 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Saturday, January 29, 2022 3:09:33 PM
Senti, Did that shareholder meeting preceed about March of 2015 or a little bit later or was it after the fact?
I went back and looked when Les spoke with Ike regarding the additional 31 patients... the question was asked and answered prior to the 2019 ASM on January 31, 2019. A bunch of us on this board listed and voted for the questions we wanted asked of management at the ASM. Ike took the list of questions and submitted them to Les AND Linda via email.
Les called Ike back and gave him the answers. Regarding the 31 patients who were enrolled in the trial AFTER the screening halt, this is what Les told Ike (remember, LP was also sent the list of questions). FYI: the number 18 in the quote below simply means that was the number of the question from the list we'd all voted on.
4. (18 Distribution of final 31 patients): ALL PATIENTS WERE RANDOMIZED You can't just put a group in one arm or the other. NWBO had nothing to do with which patients ended up in which arm. Because of the large number of sites, the final randomization may not have been exactly 2:1 but may have been off by a few people one way or the other.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146490681
The bold, red, cap emphasis is mine.
And here is the response to a question regarding the hold:
3. (01 Hold): The FDA was involved with the hold and discussing it right before applying for approval does not seem like a wise thing to do.
So there you have it folks. Feel free to keep thinking the randomization was otherwise, but this is what the company has said, many times, trust me.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
